![](/img/cover-not-exists.png)
36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, C., Tannapfel, A., Meiler, J., Luley, K.B., Kopp, H.G., Homann, N., Hofheinz, R.D., Schmalenberg, H., Probst, S., Haag, G.M., Egger, M., Behringer, D.M., Stoehlmacher, J., Prasnikar, N., BlocVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(15)30080-0
Date:
September, 2015
File:
PDF, 61 KB
english, 2015